XML 38 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Cash flow from operating activities:    
Net income $ 1,430.1 $ 2,999.0
Adjustments to reconcile net income to net cash flow from operating activities:    
Depreciation and amortization 219.8 232.8
Impairment of intangible assets 585.9 0.0
Acquired in-process research and development 18.0 75.0
Share-based compensation 124.1 115.8
Gain on interest rate swap 0.0 (3.3)
Contingent consideration (33.5) 5.5
Deferred income taxes (622.8) 180.2
(Gain) loss on strategic investments 283.6 (39.7)
Loss on equity method investment (16.1) 1.6
Other 112.4 83.7
Changes in operating assets and liabilities, net:    
Accounts receivable 211.5 (268.8)
Due from anti-CD20 therapeutic programs (8.7) 149.1
Inventory (193.8) (188.2)
Accrued expense and other current liabilities (188.4) (441.4)
Income tax assets and liabilities 171.5 504.6
Other changes in operating assets and liabilities, net (97.3) 9.9
Net cash flow provided by operating activities 1,996.3 3,415.8
Cash flows from investing activities:    
Proceeds from sales and maturities of marketable securities 1,452.7 3,879.9
Purchases of marketable securities (1,626.9) (3,753.9)
Proceeds from divestiture of Hillerød, Denmark manufacturing operations 28.1 0.0
Purchases of property, plant and equipment (164.5) (254.7)
Acquired in-process research and development 0.0 (75.0)
Acquisitions of intangible assets 0.0 (37.0)
Proceeds from sales of strategic investments 91.2 0.5
Other 2.0 (7.8)
Net cash flow used in investing activities (217.4) (389.8)
Cash flows from financing activities:    
Purchases of treasury stock (1,050.0) (5,029.1)
Payments related to issuance of stock for share-based compensation arrangements, net (14.2) (19.2)
Repayment of borrowings and premiums paid on debt exchange (170.0) 0.0
Proceeds from borrowings 0.0 2,967.3
Repayment of borrowings 0.0 (1,500.0)
Cash proceeds from settlement of swap 0.0 3.3
Net distribution to noncontrolling interest (94.8) 0.0
Other (20.5) 19.0
Net cash flow used in financing activities (1,349.5) (3,558.7)
Net increase (decrease) in cash and cash equivalents 429.4 (532.7)
Effect of exchange rate changes on cash and cash equivalents 18.6 (3.9)
Cash and cash equivalents, beginning of the period 1,331.2 2,913.7
Cash and cash equivalents, end of the period 1,742.0 2,384.9
Sangamo    
Cash flows from investing activities:    
Purchase of Sangamo Therapeutics, Inc. stock $ 0.0 $ (141.8)